tumor-bearing mice, when compared with normal control nonirradiated mice (Figures 2c and d) . Furthermore, exogenous rmHMGB1 (recombinant mouse HMGB1) showed its capacity to upregulate the IL6 and miR-21 expression level in a TLR4-dependent manner (Figure 2e ). These data indicate the possible important role of HMGB1/TLR4/IL6-miR-21 pathway in radiation-induced carcinogenesis.
The t(15;17) translocation that results in the PML/RARA fusion is the disease-defining lesion in nearly all cases of acute promyelocytic leukemia (APL). 1 Despite the importance of the PML/RARA fusion for the pathogenesis of APL, it is most likely not sufficient to cause leukemia. The long latency, incomplete penetrance and additional cytogenetic changes accompanying the onset and progression of the disease in the murine APL models strongly suggest that additional mutations are required for the development of APL. 2 In newly diagnosed patients with APL, approximately 40% have leukemic cells with secondary abnormalities. 3 Collaborating mutations affecting the FLT3 Abbreviation: APL, acute promyelocytic leukemia. We generated at least 5.2 Gb of mapped exome sequence per sample and thereby covered at least 81% of RefSeq coding exon positions with a minimum read depth of 10.
Letters to the Editor receptor tyrosine kinase are found in about 20-30% of APL patients and a synergism between FLT3 mutations and PML/ RARA was also observed in murine APL models. 4 Recently, we used whole transcriptome sequencing to screen systematically for leukemia-specific mutations in a patient with karyotypically normal acute myeloid leukemia (AML). 5 As an alternative approach, in the present study, we performed wholeexome sequencing of three APL patients to identify somatic mutations. All patients were diagnosed with PML/RARA-positive APL and achieved complete remission, following treatment with arsenic trioxide at the Shariati Hospital in Tehran (Iran). 6 Mutations in FLT3 and NPM1 were excluded for all the three APL patients. After leukocyte recovery, a remission sample from peripheral blood was taken. Informed consent and ethical approval for scientific use of the sample including genetic studies was obtained. Genomic DNA was extracted from the patients' bone marrow (diagnostic APL samples) or peripheral blood (remission samples).
Using exon capturing from genomic DNA (SureSelect human all exon 38 Mb kit, version 1, Agilent Technologies, Santa Clara, CA, USA), followed by 76-bp paired-end sequencing on an Illumina Genome Analyzer IIx platform (Illumina, San Diego, CA, USA), we generated at least 5 Gb of exome sequence for each APL and corresponding samples (Table 1) . We achieved a minimum 10-fold coverage of at least 81% of RefSeq coding exon positions in each sample (Table 1 , Supplementary Figure S1) . By comparing the APL exome sequence with the remission exome sequence, we identified APL-specific genetic variants. Read mapping and data analysis were performed as described before. 5 In brief, we called high-evidence variants in the APL samples and then we excluded annotated polymorphisms (dbSNP130), non-coding positions and all positions with evidence of a variant in the corresponding remission samples. Abbreviation: APL, acute promyelocytic leukemia. Leukemia-specific mutations confirmed by Sanger sequencing (see also Figure 1 ). For each mutation, the table shows affected gene, genomic position, genotype in APL and remission, resulting amino-acid change, corresponding ensembl transcript and read depth. Figure 1 Leukemia-specific mutations in three APL patients confirmed by Sanger sequencing of genomic DNA. Chromatograms are shown for both the APL and the corresponding remission samples.
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The resulting candidate variants were annotated and all variants resulting in synonymous mutations were removed. Then, the alignments of the remaining candidate variants were inspected, and variants in empirically error-prone sequences, such as highly repetitive regions, were excluded. Finally, we were able to confirm 3-6 non-synonymous coding mutations per patient by Sanger sequencing of genomic DNA (Table 2, Figure 1 ).
The number of somatic mutations found per patient is within the range of previous findings of 5-12 non-synonymous coding mutations per patient in the genomes and transcriptomes of cytogenetically normal AML. 5, 7, 8 Interestingly, we confirmed mutations in genes that are known targets in leukemia, including a single base pair insertion in WT1 (R370fs, Patient number 1) as well as a KRAS missense mutation (G12V, Patient number 2). WT1 mutations are found with a frequency of about 10% in cytogenetically normal AML. 9 The WT1 insertion found in the present study deletes the C-terminal zinc fingers of the WT1 protein and thereby results, with all likelihood, in a non-DNA-binding form of the protein, which might act in a dominant-negative fashion. Oncogenic KRAS mutations are found in about 10% of APL patients and were previously shown to collaborate with PML/RARA to induce leukemia in a murine model. 10 In addition, we found mutations in genes with a strong potential to be involved in APL pathogenesis: Missense mutations in the highly divergent homeobox gene HDX, as well as missense mutations in the tyrosine kinase gene LYN. Homeobox transcription factor genes are master regulators of cell identity and have a key role in normal and malignant hematopoiesis.
11 Notably, LYN is involved in FLT3-internal tandem duplication signaling in AML, 12 and somatic LYN mutations were found in various solid tumors, including breast cancer and glioma (Catalogue of Somatic Mutations in CancerFCOSMIC, Sanger Institute). We also found a missense mutation in the discoidin domain receptor tyrosine kinase 2 gene (DDR2). Although somatic mutations of both DDR2 and the related receptor tyrosine kinase DDR1 were found in a variety of solid tumors (COSMIC, Sanger Institute), so far only a single DDR1 mutation has been reported in AML. 13 Moreover, we report a missense mutation in the APOC2 (apolipoprotein C-II) gene, which is expressed during myelomonocytic differentiation.
14 Although a role for APOC2 in APL has not been described, the genotype of another apolipoprotein, APOE, determines survival in chronic lymphocytic leukemia. 15 Finally, we identified several mutations affecting poorly characterized genes (for example, in TMEM56, NGLY1, GPR158, CYB5D2) without any known functions in blood cells, or mutations in genes with well-known functions that are most likely not relevant for hematological malignancy. For example, SEMG2 encodes a seminal protein and CUBN encodes the intrinsic factor, which is secreted by parietal cells in the gastric epithelium.
We demonstrated that sequencing APL exomes is an efficient method to identify genes with tumor-specific somatic point mutations and short indels. Although two out of the three APL patients carried mutations in KRAS or WT1, in the third APL sample, no previously known mutational targets were affected. No overlap between the mutations in the three APL patients was found, indicating that the spectrum of mutations that may cooperate with PML/RARA might be large and diverse. Our findings demonstrate that exome sequencing is an efficient method to screen for leukemia-specific mutations that may collaborate with the PML/RARA fusion during the onset and progression of APL.
It will be very challenging to determine whether the increasing numbers of tumor-specific somatic mutations are drivers of malignancy or mere passengers that do not contribute to tumor onset or progression. Screening of these candidate genes in large patient cohorts will provide information about their mutation frequency.
